Inhibikase Therapeutics (IKT) Leases (2022 - 2025)
Historic Leases for Inhibikase Therapeutics (IKT) over the last 4 years, with Q2 2025 value amounting to $34918.0.
- Inhibikase Therapeutics' Leases fell 7867.76% to $34918.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $34918.0, marking a year-over-year decrease of 7867.76%. This contributed to the annual value of $101437.0 for FY2024, which is 5435.43% down from last year.
- Inhibikase Therapeutics' Leases amounted to $34918.0 in Q2 2025, which was down 7867.76% from $68719.0 recorded in Q1 2025.
- Inhibikase Therapeutics' Leases' 5-year high stood at $353250.0 during Q3 2022, with a 5-year trough of $34918.0 in Q2 2025.
- For the 4-year period, Inhibikase Therapeutics' Leases averaged around $202497.2, with its median value being $207843.5 (2023).
- In the last 5 years, Inhibikase Therapeutics' Leases crashed by 2920.31% in 2023 and then crashed by 7867.76% in 2025.
- Inhibikase Therapeutics' Leases (Quarter) stood at $328643.0 in 2022, then tumbled by 32.38% to $222227.0 in 2023, then plummeted by 54.35% to $101437.0 in 2024, then tumbled by 65.58% to $34918.0 in 2025.
- Its Leases was $34918.0 in Q2 2025, compared to $68719.0 in Q1 2025 and $101437.0 in Q4 2024.